Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
Personalis, Inc. (NASDAQ: PSNL) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Personalis, Inc. (NASDAQ: PSNL) had its price target lowered by analysts at Needham & Company LLC from $7.25 to $7.00. They now have a "buy" rating on the stock.